Sitagliptin and Simvastatin Interaction Causing Rhabdomyolysis and AKI

Abstract EN

We report a case of rhabdomyolysis and severe acute kidney injury (AKI) requiring dialysis in a 69-year-old male who was recently started on sitagliptin while on chronic simvastatin therapy.

This potential interaction is not included in the package insert for sitagliptin.

A comprehensive literature review revealed six previous reports of rhabdomyolysis due to drug interaction between sitagliptin and statins including simvastatin, lovastatin, and atorvastatin.

Of these six cases, only two had developed rhabdomyolysis-associated AKI, none of which were severe enough to require dialysis.

As patients are commonly prescribed statins and sitagliptin for treatment of dyslipidemia and diabetes, health care professionals should be aware of this potential drug interaction and closely monitor their patients for signs and symptoms of rhabdomyolysis and AKI.

This case highlights the importance of conducting further studies on the risk of muscular toxicity of sitagliptin especially when administered concurrently with statins.